Blog

Artificial Intelligence behind EndoTool – A tool, not a replacement

Nurse touch her tablet with copy space for text display.

Earlier this month, the blog titled ‘Innovative Thinking > Product Selling’ summarized the idea of selling a concept instead of selling a product. The article informed the reader that in order to sell an innovative technology, they have to not only change what executives think, but also how they think.

When it comes to recommending an insulin dose for hospitalized patients, EndoTool replaces dated and linear protocols with personalized patient treatment. The magic behind EndoTool’s innovation is to use sophisticated and predictive algorithms to optimize insulin dosing for even the most complex patients. In turn, institutions avoid costly hospital acquired infections and hospital acquired conditions as the result of poor glucose control. read more…

The Risk of Hypoglycemia in Type 2 Diabetes

Diabetes-Type-2_v2

Hypoglycemia is a condition characterized by abnormally low blood glucose (blood sugar) levels, usually less than 70 mg/dL. This condition is recognized to be one of the main restrictions in achieving normal control in type 1 diabetes. Historically, the risk of hypoglycemia has been considered lower in type 2 diabetes, however, with the increasing use of insulin to treat type 2 diabetes, the occurrence of hypoglycemia has the potential to intensify.

The focus on the relationship between hypoglycemia and type 1 diabetes is due to the frequency of hypoglycemia in these patients. Per the American Diabetes Association, on average, people with type 1 diabetes experience hypoglycemia around twice a week. This number equates to a prevalence of 30% – 40% a year. read more…

Monarch Medical Technologies Announces New Chief Executive Officer

Monarch Medical Technologies, the market-leading clinical decision support software committed to the safest insulin dosing, today announced that Linda Beneze has joined the company as its new chief executive officer. Formerly the Chief Executive Officer at Medical Technology Products, Beneze has extensive experience building and leading global high-performance teams with expertise in medical device, clinical trial software, bioinformatics, and data management.

“After an extensive selection process, we are delighted to have Linda Beneze lead the company in an evolving and expanding market of inpatient glycemic control. Linda brings a wealth of experience in improving outcomes and enhancing patient and provider safety, alongside her unique blend of leadership experience,” said Christophe Mallard, managing member of private investment firm Eigen Capital Holdings LLC which controls Monarch Medical Technologies. “Linda shares our commitment to patient safety, passion for improving hospital outcomes, and excitement for our future. We look forward to strong continued growth under her leadership.” read more…

Innovative Thinking > Product Selling

Innovative-03-01-17-v2

Recently, an article written by Prashant Dedhia was shared on LinkedIn titled, ‘Don’t sell a product, sell a whole new way of thinking’. The mantra of selling an idea instead of a product is a concept often overlooked in healthcare.

In order to sell innovative technology to executives, you have to not only change what those people think, but how they think. The author writes about companies that successfully market and sell innovation and are able to shift how people think not only about their product, but about themselves, the market, and the world. read more…

Glucose Variability and Tight Glycemic Control

When it comes to glucose control, glucose variability, and the risk for hypoglycemia, often times they can be related. Even though reducing hyperglycemia and leveling HbA1c values of seven percent or less result in decreased risk of complications, the risk for hypoglycemia increases when glycemic control is tightened. Thus, hypoglycemia has been viewed as the barricade to tight glycemic control. Because of this, patients with diabetes face the ultimate problem: reducing average glycemic levels and hyperglycemia following meals, while at the same time, trying to avoid hypoglycemia.

Hands hold and protect scales of justice and law concept vector illustration

What is the strategy behind achieving optimization?

The strategy can only be successful if it reduces glucose variability. Bringing the average glycemia down is only attainable if glucose variability is restrained. If glucose variability is not restrained, blood glucose variations would unavoidably enter hypoglycemia.

How can glucose variability be measured?

There are different ways to monitor glucose and each direction results in different determinations of glucose variability. read more…

Insulin – Lifesaver or Killer?: Part 1

Death-by-Insulin

Patient risks of severe hypoglycemia

Edward Mason is an eighteen-year old male with a height of 175.26 cm (5’9) and a weight of 72.57 kg (160 lbs).  Edward is admitted to the Emergency Room with severe abdominal pain, nausea, vomiting, and weakness. He is hyperglycemic with no prior history of diabetes.

After examination, Edward is diagnosed with diabetic ketoacidosis (DKA) and a new diagnosis of Type 1 diabetes. He is then admitted to the Intensive Care Unit and placed on an insulin drip for treatment. read more…

Why Glycemic Control is Critical in the Labor and Delivery Unit

Gestational Diabetes

According to the American Diabetes Association (ADA), pregnant women who have never had diabetes before but who have high blood glucose (sugar) levels during pregnancy are said to have gestational diabetes. According to a 2014 analysis by the Centers for Disease Control and Prevention, the prevalence of gestational diabetes among U.S. women is as high as 9.2%.

read more…

Page 4 of 10« First...23456...10...Last »